Morgan Stanley analyst Stephen Byrd maintains ONE Gas (NYSE:OGS) with a Equal-Weight and raises the price target from $82 to $89.
Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
